TIGER-2 Information News and Information Our Business Our Background Our Strategy Our People Board of Directors Company Officers Senior Staff Company Photo Community Involvement Awards & Recognition Community Team Spirit Philanthropic Efforts Contact Us Directions Careers Careers Join Our Team College Intern Program Overview AzaSite® Restasis® Elestat® Pipeline Prolacria™ (diquafosol tetrasodium) for dry eye diquafosol clinical trials dry eye disease Denufosol tetrasodium for CF denufosol clinical trials cystic fibrosis INS115644 for glaucoma licensing agreement press release About Research Overview of Research and Preclinical Development History of Research at Inspire Informatics Chemistry Intellectual Property Deeper Science Inspire's Screening Assay Nucleotide Therapeutics Dinucleotides Nucleotoids New Discoveries About Development Development Mission Statement Development Organization Science and Technology Introduction to Inspire Technology Understanding P2Y2 Nucleotides Publications & Presentations Our Vision About Us Our Partners R&D and Commercial Highlights Our Areas of Interest Submit Your Discovery Partnership News Contact Us Investor Overview Online Investor Kit Press Releases Stock Quote Annual Reports SEC Filings Financial Data Corporate Governance Management IR Events Webcasts & Presentations Analyst Coverage E-mail Alerts & Sign-Up Contacts & Info Request Principles and Practices Board of Directors Committees Audit Committee Charter Audit Committee Members Compensation Committee Charter Compensation Committee Members Corporate Governance Committee Charter Corporate Governance Committee Members Codes and Policies Code of Conduct and Business Ethics Code of Conduct: Promotional Interactions with Health Care Professionals Policies Regarding Criteria for Nomination to the Board of Directors and Procedures for Nomination of Directors by Stockholders Stockholder Communication Policy Whistlerblower Policy Page last updated: 30-Jul-2008
TIGER-2 Information News and Information
Our Business
Our Background Our Strategy Our People Board of Directors Company Officers Senior Staff Company Photo Community Involvement Awards & Recognition Community Team Spirit Philanthropic Efforts
Contact Us Directions Careers Careers Join Our Team College Intern Program Overview AzaSite® Restasis® Elestat® Pipeline Prolacria™ (diquafosol tetrasodium) for dry eye diquafosol clinical trials dry eye disease Denufosol tetrasodium for CF denufosol clinical trials cystic fibrosis INS115644 for glaucoma licensing agreement press release
About Research Overview of Research and Preclinical Development History of Research at Inspire Informatics Chemistry Intellectual Property Deeper Science Inspire's Screening Assay Nucleotide Therapeutics Dinucleotides Nucleotoids New Discoveries About Development Development Mission Statement Development Organization Science and Technology Introduction to Inspire Technology Understanding P2Y2 Nucleotides Publications & Presentations Our Vision About Us Our Partners R&D and Commercial Highlights Our Areas of Interest Submit Your Discovery Partnership News Contact Us Investor Overview Online Investor Kit Press Releases Stock Quote Annual Reports SEC Filings Financial Data Corporate Governance Management IR Events Webcasts & Presentations Analyst Coverage E-mail Alerts & Sign-Up Contacts & Info Request
Principles and Practices Board of Directors Committees Audit Committee Charter Audit Committee Members Compensation Committee Charter Compensation Committee Members Corporate Governance Committee Charter Corporate Governance Committee Members Codes and Policies Code of Conduct and Business Ethics Code of Conduct: Promotional Interactions with Health Care Professionals Policies Regarding Criteria for Nomination to the Board of Directors and Procedures for Nomination of Directors by Stockholders Stockholder Communication Policy Whistlerblower Policy
Page last updated: 30-Jul-2008
